Vimarsana
Biggest News Aggregation in the World

Page 8 - Maintenance Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Maintenance Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Maintenance Phase Today - Breaking & Trending Today

When parents refuse to travel: Parenting advice from Care and Feeding. - Vimarsana News

When parents refuse to travel: Parenting advice from Care and Feeding.

Parenting advice on travel, grandparents, and the birds and the bees.

Source: slate.com
What Are the Risks & Side-Effects of Giving Kids Weight Loss Drugs? – SheKnows - Vimarsana News

What Are the Risks & Side-Effects of Giving Kids Weight Loss Drugs? – SheKnows

With word that Wegovy, among other weight loss drugs, have been approved for kids and teens, what should parents know about safety and side-effects?

The Best Food Podcasts of 2023, According to BA Editors - Vimarsana News

The Best Food Podcasts of 2023, According to BA Editors

"Be My Guest with Ina Garten," "Gastropod," "The One Recipe," and more. These are 11 of the food podcasts we can't stop listening to.

EQS-News: Immunic, Inc.: Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis - Vimarsana News

EQS-News: Immunic, Inc.: Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis

Issuer: Immunic, Inc. / Key word(s): Study results/Strategic Company Decision Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe

EQS-News: Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis - Vimarsana News

EQS-News: Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis

Issuer: Immunic, Inc. / Key word(s): Study results/Strategic Company Decision Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis 05.04.2023 / 12:30 CET/CEST The issuer is solely responsible for the cont...